Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity

Sylvia Lee-Huang, Vladimir Maiorov, Philip L. Huang, Angela Ng, Chul Lee Hee, Young Tae Chang, Neville Kallenbach, Paul L. Huang, Hao Chia Chen

Research output: Contribution to journalArticle

Abstract

We previously reported that lysozyme accounts for anti-HIV activity associated with the β-core fraction of human chorionic gonadotropin [Lee-Huang, S., Huang, P. L., Sun, Y., Kung, H. F., Blithe, D. L. & Chen, H. C. (1999) Proc Natl Acad Sci U S A 96, 2678-81]. To define the structural and sequence requirements for anti-HIV activity, we carried out peptide fragmentation and activity mapping of human lysozyme. We identified two peptides that consist of 18 and 9 amino acids of human lysozyme (HL18 and HL9), corresponding to residues 98-115 and 107-115. HL18 and HL9 are potent inhibitors of HIV-1 infection and replication with EC50S of 50 to 55 nM, comparable to intact lysozyme. Scrambling the sequence or substitution of key arginine or tryptophan residues results in loss of antiviral activity. HL9, with the sequence RAWVAWRNR, is the smallest peptide we identified with full anti-HIV activity. It forms a pocket with its basic residues on the surface of the molecule. HL9 exists as an α-helix in native human lysozyme, in a region of the protein distinct from the muramidase catalytic site. Monte Carlo peptide folding energy minimizing simulation modeling and CD studies indicate that helical propensity does not correlate with antiviral activity. HL9 blocks HIV-1 viral entrance and replication, and modulates gene expression of HIV-infected cells, affecting pathways involved in survival, stress, TGFβ, p53, NFκB, protein kinase C and hedgehog signaling.

Original languageEnglish (US)
Pages (from-to)4648-4655
Number of pages8
JournalBiochemistry
Volume44
Issue number12
DOIs
StatePublished - Mar 29 2005

Fingerprint

Muramidase
HIV
Peptides
Antiviral Agents
HIV-1
Solar System
Chorionic Gonadotropin
Population Groups
Gene expression
Human Activities
Tryptophan
Sun
Protein Kinase C
HIV Infections
Arginine
Catalytic Domain
Substitution reactions
Gene Expression
Amino Acids
Molecules

ASJC Scopus subject areas

  • Biochemistry

Cite this

Lee-Huang, S., Maiorov, V., Huang, P. L., Ng, A., Hee, C. L., Chang, Y. T., ... Chen, H. C. (2005). Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. Biochemistry, 44(12), 4648-4655. https://doi.org/10.1021/bi0477081

Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. / Lee-Huang, Sylvia; Maiorov, Vladimir; Huang, Philip L.; Ng, Angela; Hee, Chul Lee; Chang, Young Tae; Kallenbach, Neville; Huang, Paul L.; Chen, Hao Chia.

In: Biochemistry, Vol. 44, No. 12, 29.03.2005, p. 4648-4655.

Research output: Contribution to journalArticle

Lee-Huang, S, Maiorov, V, Huang, PL, Ng, A, Hee, CL, Chang, YT, Kallenbach, N, Huang, PL & Chen, HC 2005, 'Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity', Biochemistry, vol. 44, no. 12, pp. 4648-4655. https://doi.org/10.1021/bi0477081
Lee-Huang, Sylvia ; Maiorov, Vladimir ; Huang, Philip L. ; Ng, Angela ; Hee, Chul Lee ; Chang, Young Tae ; Kallenbach, Neville ; Huang, Paul L. ; Chen, Hao Chia. / Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. In: Biochemistry. 2005 ; Vol. 44, No. 12. pp. 4648-4655.
@article{e327c66bb15341c6a5e6a1c746bc02a8,
title = "Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity",
abstract = "We previously reported that lysozyme accounts for anti-HIV activity associated with the β-core fraction of human chorionic gonadotropin [Lee-Huang, S., Huang, P. L., Sun, Y., Kung, H. F., Blithe, D. L. & Chen, H. C. (1999) Proc Natl Acad Sci U S A 96, 2678-81]. To define the structural and sequence requirements for anti-HIV activity, we carried out peptide fragmentation and activity mapping of human lysozyme. We identified two peptides that consist of 18 and 9 amino acids of human lysozyme (HL18 and HL9), corresponding to residues 98-115 and 107-115. HL18 and HL9 are potent inhibitors of HIV-1 infection and replication with EC50S of 50 to 55 nM, comparable to intact lysozyme. Scrambling the sequence or substitution of key arginine or tryptophan residues results in loss of antiviral activity. HL9, with the sequence RAWVAWRNR, is the smallest peptide we identified with full anti-HIV activity. It forms a pocket with its basic residues on the surface of the molecule. HL9 exists as an α-helix in native human lysozyme, in a region of the protein distinct from the muramidase catalytic site. Monte Carlo peptide folding energy minimizing simulation modeling and CD studies indicate that helical propensity does not correlate with antiviral activity. HL9 blocks HIV-1 viral entrance and replication, and modulates gene expression of HIV-infected cells, affecting pathways involved in survival, stress, TGFβ, p53, NFκB, protein kinase C and hedgehog signaling.",
author = "Sylvia Lee-Huang and Vladimir Maiorov and Huang, {Philip L.} and Angela Ng and Hee, {Chul Lee} and Chang, {Young Tae} and Neville Kallenbach and Huang, {Paul L.} and Chen, {Hao Chia}",
year = "2005",
month = "3",
day = "29",
doi = "10.1021/bi0477081",
language = "English (US)",
volume = "44",
pages = "4648--4655",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity

AU - Lee-Huang, Sylvia

AU - Maiorov, Vladimir

AU - Huang, Philip L.

AU - Ng, Angela

AU - Hee, Chul Lee

AU - Chang, Young Tae

AU - Kallenbach, Neville

AU - Huang, Paul L.

AU - Chen, Hao Chia

PY - 2005/3/29

Y1 - 2005/3/29

N2 - We previously reported that lysozyme accounts for anti-HIV activity associated with the β-core fraction of human chorionic gonadotropin [Lee-Huang, S., Huang, P. L., Sun, Y., Kung, H. F., Blithe, D. L. & Chen, H. C. (1999) Proc Natl Acad Sci U S A 96, 2678-81]. To define the structural and sequence requirements for anti-HIV activity, we carried out peptide fragmentation and activity mapping of human lysozyme. We identified two peptides that consist of 18 and 9 amino acids of human lysozyme (HL18 and HL9), corresponding to residues 98-115 and 107-115. HL18 and HL9 are potent inhibitors of HIV-1 infection and replication with EC50S of 50 to 55 nM, comparable to intact lysozyme. Scrambling the sequence or substitution of key arginine or tryptophan residues results in loss of antiviral activity. HL9, with the sequence RAWVAWRNR, is the smallest peptide we identified with full anti-HIV activity. It forms a pocket with its basic residues on the surface of the molecule. HL9 exists as an α-helix in native human lysozyme, in a region of the protein distinct from the muramidase catalytic site. Monte Carlo peptide folding energy minimizing simulation modeling and CD studies indicate that helical propensity does not correlate with antiviral activity. HL9 blocks HIV-1 viral entrance and replication, and modulates gene expression of HIV-infected cells, affecting pathways involved in survival, stress, TGFβ, p53, NFκB, protein kinase C and hedgehog signaling.

AB - We previously reported that lysozyme accounts for anti-HIV activity associated with the β-core fraction of human chorionic gonadotropin [Lee-Huang, S., Huang, P. L., Sun, Y., Kung, H. F., Blithe, D. L. & Chen, H. C. (1999) Proc Natl Acad Sci U S A 96, 2678-81]. To define the structural and sequence requirements for anti-HIV activity, we carried out peptide fragmentation and activity mapping of human lysozyme. We identified two peptides that consist of 18 and 9 amino acids of human lysozyme (HL18 and HL9), corresponding to residues 98-115 and 107-115. HL18 and HL9 are potent inhibitors of HIV-1 infection and replication with EC50S of 50 to 55 nM, comparable to intact lysozyme. Scrambling the sequence or substitution of key arginine or tryptophan residues results in loss of antiviral activity. HL9, with the sequence RAWVAWRNR, is the smallest peptide we identified with full anti-HIV activity. It forms a pocket with its basic residues on the surface of the molecule. HL9 exists as an α-helix in native human lysozyme, in a region of the protein distinct from the muramidase catalytic site. Monte Carlo peptide folding energy minimizing simulation modeling and CD studies indicate that helical propensity does not correlate with antiviral activity. HL9 blocks HIV-1 viral entrance and replication, and modulates gene expression of HIV-infected cells, affecting pathways involved in survival, stress, TGFβ, p53, NFκB, protein kinase C and hedgehog signaling.

UR - http://www.scopus.com/inward/record.url?scp=15444380147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444380147&partnerID=8YFLogxK

U2 - 10.1021/bi0477081

DO - 10.1021/bi0477081

M3 - Article

C2 - 15779891

AN - SCOPUS:15444380147

VL - 44

SP - 4648

EP - 4655

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 12

ER -